Telix Completes TLX250-CDx (Zircaix™) BLA Submission for Kidney Cancer Imaging


MELBOURNE, Australia, June 03, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for its investigational radiodiagnostic PET1 agent, TLX250-CDx (Zircaix™2, 89Zr-DFO-girentuximab), for the characterisation of renal masses as clear cell renal cell carcinoma (ccRCC).

Go here to see the original:
Telix Completes TLX250-CDx (Zircaix™) BLA Submission for Kidney Cancer Imaging

Related Posts